Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

H9414

Sigma-Aldrich

Halofantrine hydrochloride

≥98% (HPLC), solid

Sinónimos:

1,3-Dichloro-a-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride, Halfan

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C26H30Cl2F3NO · HCl
Número de CAS:
36167-63-2
Peso molecular:
536.88
Número CE:
252-895-4
Número MDL:
MFCD00879136
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329815264
NACRES:
NA.77

Nivel de calidad

100

Ensayo

≥98% (HPLC)

Formulario

solid

condiciones de almacenamiento

desiccated

color

white to off-white

solubilidad

DMSO: >10 mg/mL

emisor

GlaxoSmithKline

temp. de almacenamiento

2-8°C

cadena SMILES

Cl.CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c3cc(ccc13)C(F)(F)F

InChI

1S/C26H30Cl2F3NO.ClH/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23;/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3;1H

Clave InChI

WANGFTDWOFGECH-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Acciones bioquímicas o fisiológicas

Halofantrine is a blocker of delayed rectifier potassium current via the inhibition of hERG channel.

Características y beneficios

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Frases de peligro

H413

Consejos de prudencia

P273 - P501

Clasificaciones de peligro

Aquatic Chronic 4

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000397169
0000397169
0000397168
0000279497
0000228791

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

H Tie et al.
British journal of pharmacology, 130(8), 1967-1975 (2000-08-22)
Halofantrine is a widely used antimalarial agent which has been associated with prolongation of the 'QT interval' of the electrocardiogram (ECG), torsades de pointes and sudden death. Whilst QT prolongation is consistent with halofantrine-induced increases in cardiac ventricular action potential
René Holm et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(2), 281-287 (2012-04-03)
The bioavailability of the poorly soluble model drug halofantrine, dosed in a soy bean oil solution or in a self-nanoemulsifying drug delivery system (SNEDDS), at two levels of lipid, was assessed in rats. Three rat models were used: intact rats
Jigar P Patel et al.
Chirality, 24(7), 558-565 (2012-05-17)
Experimental hyperlipidemia has shown to decrease cytochrome P450 3A4 and 2C11 expression and to increase liver concentrations and the plasma protein binding of halofantrine (HF) enantiomers. The present study examined the effect of hyperlipidemic (HL) serum on the metabolism of
Martin Traebert et al.
European journal of pharmacology, 484(1), 41-48 (2004-01-20)
Several antimalarial drugs are known to produce a QT interval prolongation via a blockade of the rapidly activating delayed rectifier K+ current (IKr), encoded by the human-ether-a-go-go-related gene (hERG). We investigated the influence of lumefantrine and its major metabolite desbutyl-lumefantrine
Ji-Hyun Lee et al.
PloS one, 7(8), e42573-e42573 (2012-08-21)
Anticancer therapies that target single signal transduction pathways often fail to prevent proliferation of cancer cells because of overlapping functions and cross-talk between different signaling pathways. Recent research has identified that balanced multi-component therapies might be more efficacious than highly
Ver todos los artículos relacionados

Artículos

Potassium Channels

We offer many products related to potassium channels for your research needs.

Potassium Channels

We offer many products related to potassium channels for your research needs.

Potassium Channels

We offer many products related to potassium channels for your research needs.

Potassium Channels

We offer many products related to potassium channels for your research needs.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico